PMID: 9416983Jan 7, 1998Paper

Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals

Journal of Human Hypertension
J S JensenG Jensen

Abstract

Microalbuminuria has been proposed as a potential atherosclerotic risk factor in hypertensive individuals. The aim of this cross-sectional population study was to analyse whether microalbuminuria is related to a higher prevalence of cardiovascular disease, and a more atherogenic risk profile, and reversely related to the use of antihypertensive drugs. In a major health screening at the State University Hospital in Copenhagen, including urinary albumin excretion, glomerular filtration rate, blood pressure (BP), electrocardiogram, body mass index, plasma lipoproteins, fibrinogen, and albumin, and information regarding a history of acute myocardial infarction, smoking, and antihypertensive drugs, 1254 participants without diabetes mellitus or renal/urinary tract disease had arterial hypertension. Age range was 30-70 years. Microalbuminuria (nocturnal urinary albumin excretion >15 microg/min) occurred in 5%, and cardiovascular disease (previous acute myocardial infarction or electrocardiographic Q-waves) also in 5% of the study population. Microalbuminuric hypertensive subjects were characterized by higher age and systolic BP, and a male predominance, as compared to normoalbuminuric hypertensive subjects. The frequency of cardiovas...Continue Reading

Citations

Nov 1, 2011·Current Diabetes Reports·Shannon D SullivanRobert Ratner
Oct 6, 2000·The American Journal of Cardiology·C P TsioufisP K Toutouzas
Oct 24, 2002·Journal of the American College of Cardiology·Gilles F H DiercksWiek H van Gilst
Oct 29, 2003·Pulmonary Pharmacology & Therapeutics·Taco B M MonsterLolkje T W de Jong-van de Berg
Feb 19, 2002·British Journal of Clinical Pharmacology·Taco B M MonsterUNKNOWN PREVEND Study Group
Sep 4, 2010·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Matthijs F L MeijsUNKNOWN SMART study group
Dec 23, 2004·Kidney International. Supplement·Fernando de AlvaroUNKNOWN KORAL HT Investigators
Mar 4, 2008·Journal of Veterinary Internal Medicine·S SchellenbergC E Reusch
Apr 26, 2006·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Keyvan KarkoutiW Scott Beattie
Feb 3, 2016·Journal of Diabetes and Its Complications·Meng RenLi Yan
Jul 27, 2010·Journal of the American Society of Hypertension : JASH·Baris Afsar, Rengin Elsurer
Feb 6, 2007·British Journal of Clinical Pharmacology·Jarir AtthobariUNKNOWN PREVEND Study Group
Dec 8, 2006·Expert Opinion on Pharmacotherapy·R M A Van de WalR T Gansevoort
May 1, 2016·Clinica Chimica Acta; International Journal of Clinical Chemistry·S M van den BeltH J L Heerspink
Aug 31, 2012·American Journal of Hypertension·Eirini AndrikouChristodoulos Stefanadis
Apr 18, 2002·Vascular Medicine·R PedrinelliM Mariani
Jan 5, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ulla DerhaschnigMichael M Hirschl
Jul 5, 2017·Geriatrics & Gerontology International·Chun-Chin ChangShing-Jong Lin
Feb 19, 2002·Journal of Human Hypertension·R PedrinelliM Mariani
Jan 22, 2008·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Ruud M A van de WalAdriaan A Voors
Aug 14, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·K Borch-JohnsenJ S Jensen
Apr 25, 2000·Hypertension·J S JensenK Borch-Johnsen
Sep 12, 2008·Journal of Human Hypertension·C R Zamora, L X Cubeddu
May 3, 2002·Journal of Human Hypertension·G Crippa
Oct 7, 2005·Journal of Hypertension·Liffert VogtUNKNOWN Angiotensin II Receptor Antagonist Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS) Study Group
Jun 20, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Pantelis A Sarafidis, George L Bakris
Jul 7, 2007·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·C A GelukF Zijlstra
Feb 4, 2010·The Journal of Pharmacology and Experimental Therapeutics·Christine M DuganPatricia E Ganey
Jun 21, 2003·Journal of Hypertension·Massimo VolpeLuis M Ruilope
Jun 29, 2000·Journal of Hypertension·T T Rosa, P Palatini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.